Inarigivir soproxil
- Generic Name
- Inarigivir soproxil
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C25H34N7O13PS
- CAS Number
- 942123-43-5
- Unique Ingredient Identifier
- 365052M0DK
- Background
Inarigivir soproxil is under investigation in clinical trial NCT03434353 (Study to Evaluate the Antiviral Activity of Inarigivir (GS-9992) Plus Tenofovir Alafenamide (TAF) for 12 Weeks in Adults With Chronic Hepatitis B (CHB)).
- Associated Conditions
- -
- Associated Therapies
- -
Evaluating the Safety and Efficacy of Inarigivir in Non-cirrhotic Treatment Naive Subjects Infected With Hepatitis B Virus
- Conditions
- Interventions
- First Posted Date
- 2019-08-16
- Last Posted Date
- 2020-07-21
- Lead Sponsor
- F-star Therapeutics, Inc.
- Target Recruit Count
- 5
- Registration Number
- NCT04059198
- Locations
- 🇭🇰
Queen Mary Hospital, Hong Kong, Hong Kong Island, Hong Kong
🇭🇰Prince of Wales Hospital, Sha Tin, New Territories, Hong Kong
Evaluating the Safety and Efficacy of Inarigivir in Non-cirrhotic, Hepatitis B e Antigen-negative Subjects Infected With HBV Virus and Receiving or Stopping Treatment With a NUC Inhibitor
- Conditions
- Interventions
- First Posted Date
- 2019-07-17
- Last Posted Date
- 2020-07-22
- Lead Sponsor
- F-star Therapeutics, Inc.
- Target Recruit Count
- 64
- Registration Number
- NCT04023721
- Locations
- 🇨🇦
LAIR Centre, Vancouver, British Columbia, Canada
🇨🇦GI Research Institute, Vancouver, British Columbia, Canada
🇨🇦University of Calgary, Calgary, Alberta, Canada
Evaluating the Effects of Inarigivir on Immune Response and Viral Markers in Chronic Hepatitis B Patients
- First Posted Date
- 2019-04-30
- Last Posted Date
- 2020-04-29
- Lead Sponsor
- F-star Therapeutics, Inc.
- Target Recruit Count
- 8
- Registration Number
- NCT03932513
- Locations
- 🇸🇬
National University Hospital, Singapore, Singapore
Study to Evaluate the Safety and Antiviral Activity of Inarigivir Soproxil (Formerly: GS-9992) Plus Tenofovir Alafenamide (TAF) for 12 Weeks in Adults With Chronic Hepatitis B (CHB)
- First Posted Date
- 2018-02-15
- Last Posted Date
- 2022-04-04
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 123
- Registration Number
- NCT03434353
- Locations
- 🇰🇷
Catholic University of Korea, Seoul Saint Mary's Hospital, Seoul, Korea, Republic of
🇰🇷Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of
🇰🇷Asan Medical Center, Seoul, Korea, Republic of
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.